Iron overload is a leading cause of morbidity and mortality in transfusion-dependent patients. Deferasirox is the most promising iron chelator agent in several clinical scenarios. The investigators propose a retrospective study (chart review) to evaluate comprehensive iron overload management in transfusion-dependent patients treated with deferasirox for up to 5-10 years in a real clinical practice setting.
Study Type
OBSERVATIONAL
Enrollment
80
cardiac T2* in patients treated with deferasirox
change from baseline to end of study in cardiac T2\*, as measured by Magnetic Resonance, in patients with iron overload (cardiac T2\* \<20 ms at baseline)
Time frame: at least 1 year
cardiac T2* in patients treated with deferasirox
maintenance from baseline to end of study of cardiac T2\* in not iron overloaded patients (cardiac T2\* \>20 ms at baseline)
Time frame: at least 1 year
cardiac function in patient undergoing deferasirox treatment
change in left and right ejection fraction, telediastolic and telesystolic volumes, stroke volumes, cardiac output, myocardial mass, measured by Cardiac Magnetic Resonance, from baseline to end of study
Time frame: at least 1 year
change in liver iron concentration
Time frame: at least 1 year
maintenance of normal endocrine function in patients without endocrine dysfunction and improvement in disease severity in patients affected by endocrine dysfunction from baseline to end of study
Thyroid function (TSH, free triiodothyronine and free thyroxine serum free T4 levels), pancreatic cell function (basal glycemia, glycated hemoglobin level), bone mineral density (z-score) will be evaluated by the closest assessment to baseline (first deferasirox exposure) and to the end of study
Time frame: at least 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.